Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy

Cristina Basilico, Chiara Modica, Federica Maione, Elisa Vigna, Paolo M. Comoglio

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

MET, a master gene sustaining “invasive growth,” is a relevant target for cancer precision therapy. In the vast majority of tumors, wild-type MET behaves as a “stress-response” gene and relies on the ligand (HGF) to sustain cell “scattering,” invasive growth and apoptosis protection (oncogene “expedience”). In this context, concomitant targeting of MET and HGF could be crucial to reach effective inhibition. To test this hypothesis, we combined an anti-MET antibody (MvDN30) inducing “shedding” (i.e., removal of MET from the cell surface), with a “decoy” (i.e., the soluble extracellular domain of the MET receptor) endowed with HGF-sequestering ability. To avoid antibody/decoy interaction—and subsequent neutralization—we identified a single aminoacid in the extracellular domain of MET—lysine 842—that is critical for MvDN30 binding and engineered the corresponding recombinant decoyMET (K842E). DecoyMETK842E retains the ability to bind HGF with high affinity and inhibits HGF-induced MET phosphorylation. In HGF-dependent cellular models, MvDN30 antibody and decoyMETK842E used in combination cooperate in restraining invasive growth, and synergize in blocking cancer cell “scattering.” The antibody and the decoy unbridle apoptosis of colon cancer stem cells grown in vitro as spheroids. In a preclinical model, built by orthotopic transplantation of a human pancreatic carcinoma in SCID mice engineered to express human HGF, concomitant treatment with antibody and decoy significantly reduces metastatic spread. The data reported indicate that vertical targeting of the MET/HGF axis results in powerful inhibition of ligand-dependent MET activation, providing proof of concept in favor of combined target therapy of MET “expedience.”.

Original languageEnglish
Pages (from-to)1774-1785
Number of pages12
JournalInternational Journal of Cancer
Volume143
Issue number7
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Oncogenes
Ligands
Antibodies
Growth
Apoptosis
Neoplasms
SCID Mice
Neoplastic Stem Cells
Colonic Neoplasms
Genes
Anti-Idiotypic Antibodies
Transplantation
Phosphorylation
Therapeutics

Keywords

  • anti-HGF therapy
  • antibodies
  • decoy
  • MET oncogene
  • MET target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy. / Basilico, Cristina; Modica, Chiara; Maione, Federica; Vigna, Elisa; Comoglio, Paolo M.

In: International Journal of Cancer, Vol. 143, No. 7, 01.10.2018, p. 1774-1785.

Research output: Contribution to journalArticle

@article{9e6dc240e73e4354a9edfac3487578f7,
title = "Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy",
abstract = "MET, a master gene sustaining “invasive growth,” is a relevant target for cancer precision therapy. In the vast majority of tumors, wild-type MET behaves as a “stress-response” gene and relies on the ligand (HGF) to sustain cell “scattering,” invasive growth and apoptosis protection (oncogene “expedience”). In this context, concomitant targeting of MET and HGF could be crucial to reach effective inhibition. To test this hypothesis, we combined an anti-MET antibody (MvDN30) inducing “shedding” (i.e., removal of MET from the cell surface), with a “decoy” (i.e., the soluble extracellular domain of the MET receptor) endowed with HGF-sequestering ability. To avoid antibody/decoy interaction—and subsequent neutralization—we identified a single aminoacid in the extracellular domain of MET—lysine 842—that is critical for MvDN30 binding and engineered the corresponding recombinant decoyMET (K842E). DecoyMETK842E retains the ability to bind HGF with high affinity and inhibits HGF-induced MET phosphorylation. In HGF-dependent cellular models, MvDN30 antibody and decoyMETK842E used in combination cooperate in restraining invasive growth, and synergize in blocking cancer cell “scattering.” The antibody and the decoy unbridle apoptosis of colon cancer stem cells grown in vitro as spheroids. In a preclinical model, built by orthotopic transplantation of a human pancreatic carcinoma in SCID mice engineered to express human HGF, concomitant treatment with antibody and decoy significantly reduces metastatic spread. The data reported indicate that vertical targeting of the MET/HGF axis results in powerful inhibition of ligand-dependent MET activation, providing proof of concept in favor of combined target therapy of MET “expedience.”.",
keywords = "anti-HGF therapy, antibodies, decoy, MET oncogene, MET target therapy",
author = "Cristina Basilico and Chiara Modica and Federica Maione and Elisa Vigna and Comoglio, {Paolo M.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1002/ijc.31550",
language = "English",
volume = "143",
pages = "1774--1785",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy

AU - Basilico, Cristina

AU - Modica, Chiara

AU - Maione, Federica

AU - Vigna, Elisa

AU - Comoglio, Paolo M.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - MET, a master gene sustaining “invasive growth,” is a relevant target for cancer precision therapy. In the vast majority of tumors, wild-type MET behaves as a “stress-response” gene and relies on the ligand (HGF) to sustain cell “scattering,” invasive growth and apoptosis protection (oncogene “expedience”). In this context, concomitant targeting of MET and HGF could be crucial to reach effective inhibition. To test this hypothesis, we combined an anti-MET antibody (MvDN30) inducing “shedding” (i.e., removal of MET from the cell surface), with a “decoy” (i.e., the soluble extracellular domain of the MET receptor) endowed with HGF-sequestering ability. To avoid antibody/decoy interaction—and subsequent neutralization—we identified a single aminoacid in the extracellular domain of MET—lysine 842—that is critical for MvDN30 binding and engineered the corresponding recombinant decoyMET (K842E). DecoyMETK842E retains the ability to bind HGF with high affinity and inhibits HGF-induced MET phosphorylation. In HGF-dependent cellular models, MvDN30 antibody and decoyMETK842E used in combination cooperate in restraining invasive growth, and synergize in blocking cancer cell “scattering.” The antibody and the decoy unbridle apoptosis of colon cancer stem cells grown in vitro as spheroids. In a preclinical model, built by orthotopic transplantation of a human pancreatic carcinoma in SCID mice engineered to express human HGF, concomitant treatment with antibody and decoy significantly reduces metastatic spread. The data reported indicate that vertical targeting of the MET/HGF axis results in powerful inhibition of ligand-dependent MET activation, providing proof of concept in favor of combined target therapy of MET “expedience.”.

AB - MET, a master gene sustaining “invasive growth,” is a relevant target for cancer precision therapy. In the vast majority of tumors, wild-type MET behaves as a “stress-response” gene and relies on the ligand (HGF) to sustain cell “scattering,” invasive growth and apoptosis protection (oncogene “expedience”). In this context, concomitant targeting of MET and HGF could be crucial to reach effective inhibition. To test this hypothesis, we combined an anti-MET antibody (MvDN30) inducing “shedding” (i.e., removal of MET from the cell surface), with a “decoy” (i.e., the soluble extracellular domain of the MET receptor) endowed with HGF-sequestering ability. To avoid antibody/decoy interaction—and subsequent neutralization—we identified a single aminoacid in the extracellular domain of MET—lysine 842—that is critical for MvDN30 binding and engineered the corresponding recombinant decoyMET (K842E). DecoyMETK842E retains the ability to bind HGF with high affinity and inhibits HGF-induced MET phosphorylation. In HGF-dependent cellular models, MvDN30 antibody and decoyMETK842E used in combination cooperate in restraining invasive growth, and synergize in blocking cancer cell “scattering.” The antibody and the decoy unbridle apoptosis of colon cancer stem cells grown in vitro as spheroids. In a preclinical model, built by orthotopic transplantation of a human pancreatic carcinoma in SCID mice engineered to express human HGF, concomitant treatment with antibody and decoy significantly reduces metastatic spread. The data reported indicate that vertical targeting of the MET/HGF axis results in powerful inhibition of ligand-dependent MET activation, providing proof of concept in favor of combined target therapy of MET “expedience.”.

KW - anti-HGF therapy

KW - antibodies

KW - decoy

KW - MET oncogene

KW - MET target therapy

UR - http://www.scopus.com/inward/record.url?scp=85046778238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046778238&partnerID=8YFLogxK

U2 - 10.1002/ijc.31550

DO - 10.1002/ijc.31550

M3 - Article

AN - SCOPUS:85046778238

VL - 143

SP - 1774

EP - 1785

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -